716360-31-5

Basic information

• Product Name: tert-butyl 4-(3-oxopropyl)-4-phenylpiperidine-1-carboxylate
• Synonyms: tert-butyl 4-(3-oxopropyl)-4-phenylpiperidine-1-carboxylate
• CAS NO: 716360-31-5
• Molecular Weight: 317.428
• Mol File: 716360-31-5.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(3-oxopropyl)-4-phenylpiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(3-oxopropyl)-4-phenylpiperidine-1-carboxylate(716360-31-5)
• EPA Substance Registry System: tert-butyl 4-(3-oxopropyl)-4-phenylpiperidine-1-carboxylate(716360-31-5)

Safety Data

• Hazardous Substances Data: 716360-31-5(Hazardous Substances Data)

Upstream product

• 124443-68-1 1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 
• 1078-58-6 diphenylzinc 
• 1292306-46-7 C₂₁H₃₁NO₄ 
• 1292306-45-6 C₂₁H₂₉NO₄ 
• 51304-58-6 4-cyano-4-phenylpiperidine hydrochloride 
• 158144-79-7 tert-butyl 4-cyano-4-phenylpiperidine-1-carboxylate 
• 158144-80-0 1-Boc-4-phenyl-4-piperidinecarbaldehyde 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 716353-75-2 tert-butyl 4-{3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]propyl}-4-phenylpiperidine-1-carboxylate 
• 1292306-47-8 C₂₃H₃₃NO₄ 
• 1292306-44-5 ethyl 5-(4-phenylpiperidin-4-yl)pentanoate hydrochloride 
• 1292360-02-1 C₂₃H₃₅NO₄ 

Relevant articles and documents

Quaternary Centers by Nickel-Catalyzed Cross-Coupling of Tertiary Carboxylic Acids and (Hetero)Aryl Zinc Reagents

This work bridges a gap in the cross-coupling of aliphatic redox-active esters with aryl zinc reagents. Previously limited to primary, secondary, and specialized tertiary centers, a new protocol has been devised to enable the coupling of general tertiary systems using nickel catalysis. The scope of this operationally simple method is broad, and it can be used to simplify the synthesis of medicinally relevant motifs bearing quaternary centers.

SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF

The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1

We describe robust chemical approaches toward putative CCR5 scaffolds designed in our laboratories. Evaluation of analogues in the 125I-[MIP-1β] binding and Ba-L-HOS antiviral assays resulted in the discovery of 64 and 68 in the 4,4-disubstitited piperidine class H, both potent CCR5 ligands (pIC50 = 8.30 and 9.00, respectively) and HIV-1 inhibitors (pIC50 = 7.80 and 7.84, respectively, in Ba-L-HOS assay). In addition, 64 and 68 were bioavailable in rodents, establishing them as lead molecules for further optimization toward CCR5 clinical candidates.